PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
22626746-7	2012	In a multivariable analysis that adjusted for database source, maternal race/ethnicity, and anti-SSB/La status, HCQ use remained significantly associated with a decreased risk of cardiac-NL (odds ratio, 0.23; 95% confidence interval, 0.06-0.92; P=0.037).	Hydroxychloroquine	112-115	small RNA binding exonuclease protection factor La	Homo sapiens	97-100	
20447951-0	2010	Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine.	Hydroxychloroquine	173-191	small RNA binding exonuclease protection factor La	Homo sapiens	38-41	
20447951-1	2010	BACKGROUND: Based on the potential involvement of Toll-like receptor (TLR) signalling in the pathogenesis of neonatal lupus (NL), it was hypothesised that fetal exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-SSA/Ro/SSB/La antibody-associated cardiac manifestations of NL (cardiac-NL).	Hydroxychloroquine	173-191	small RNA binding exonuclease protection factor La	Homo sapiens	253-256	
20447951-1	2010	BACKGROUND: Based on the potential involvement of Toll-like receptor (TLR) signalling in the pathogenesis of neonatal lupus (NL), it was hypothesised that fetal exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-SSA/Ro/SSB/La antibody-associated cardiac manifestations of NL (cardiac-NL).	Hydroxychloroquine	193-196	small RNA binding exonuclease protection factor La	Homo sapiens	253-256	
20447951-7	2010	CONCLUSION: This case-control study suggests that, in mothers with SLE with anti-SSA/Ro/SSB/La antibodies, exposure to HCQ during pregnancy may decrease the risk of fetal development of cardiac-NL.	Hydroxychloroquine	119-122	small RNA binding exonuclease protection factor La	Homo sapiens	88-91